MARLBOROUGH, Mass., March 11, 2015 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering and developing innovative therapeutics, that address high-unmet medical needs primarily in the area of dermatology and ophthalmology, today announced that the Company's Vice President of Medical Affairs and Safety Assessment, Dr. Lyn Libertine will present at the 73rd Annual Meeting of the American Academy of Dermatology (AAD) on March 23, 2015 in San Francisco, CA. This meeting will feature world-renowned leaders presenting the latest research in the diagnosis and medical, surgical and cosmetic treatment of skin, hair and nail conditions.
Logo - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO
Dr. Libertine will present two posters that will provide an overview of the Company's first clinical compound, RXI-109, a self-delivering RNAi (sd‑rxRNA®) compound currently being evaluated in Phase 2a clinical trials. The first presentation will be held from 12:10 to 12:15 p.m. PDT, "RXI‑109 Treatment to Reduce the Formation of Keloids Following Keloidectomy". The second presentation will be held from 12:20 to 12:25 p.m. PDT, "Update on Phase 2 Clinical Trial Results of RXI‑109 Treatment to Reduce the Formation of Hypertrophic Dermal Scars". Both presentations will be at the Center E‑Poster Presentation, Center 3, in the Wound Healing and Ulcers section.
The posters will be available on the Company's website at www.rxipharma.com approximately one hour after the presentation.
About the American Academy of Dermatology
The American Academy of Dermatology was founded in 1938. It is the largest, most influential and most representative dermatology group in the United States. With a membership of more than 17,000, it represents virtually all practicing dermatologists in the United States, as well as a growing number of international dermatologists. The Academy is committed to advancing the diagnosis and medical, surgical and cosmetic treatment of the skin, hair and nails; advocating high standards in clinical practice, education, and research in dermatology; and supporting and enhancing patient care for a lifetime of healthier skin, hair and nails. This meeting will be held March 20-24, 2015 at The Moscone Center in San Francisco, CA.
About RXi Pharmaceuticals Corporation
RXi Pharmaceuticals Corporation (NASDAQ: RXII) is a biotechnology company focused on discovering and developing innovative therapeutics that address high-unmet medical needs primarily in the area of dermatology and ophthalmology. Our discovery and clinical development programs are based on siRNA technology as well as immunotherapy agents. These compounds include, but are not limited to, our proprietary, self-delivering RNAi (sd-rxRNA®) compounds for the treatment of dermal and retinal scarring. It also includes an immunomodulator, Samcyprone™, a proprietary gel formulation of diphenylcyclopropenone (DPCP), for the treatment of such disorders as alopecia areata, warts, and cutaneous metastases of melanoma.
RXi's robust pipeline, coupled with an extensive patent portfolio, provides for product and business development opportunities across a broad spectrum. We are committed to being a partner of choice for academia, small companies, and large multinationals. We welcome ideas and proposals for strategic alliances, including in- and out-licensing opportunities, to advance and further develop strategic areas of interest.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements about future expectations and planned and future development of our product candidates, technologies and partnerships. Forward-looking statements about expectations and development plans of RXi's product candidates and partnerships involve significant risks and uncertainties, including the following: risks that we may not be able to successfully develop and commercialize our product candidates; risks that product development and clinical studies may be delayed, not proceed as planned and/or be subject to significant cost over-runs; risks related to the development and commercialization of products by competitors; risks related to our ability to control the timing and terms of collaborations with third parties; and risks that other companies or organizations may assert patent rights preventing us from developing or commercializing our product candidates. Additional risks are detailed in our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption "Risk Factors." Readers are urged to review these risk factors and to not act in reliance on any forward-looking statements, as actual results may differ from those contemplated by our forward-looking statements. RXi does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release.
Contacts
RXi Pharmaceuticals Corporation
Tamara McGrillen, 508-929-3646
tmcgrillen@rxipharma.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/rxi-pharmaceuticals-to-present-at-the-73rd-annual-meeting-of-the-american-academy-of-dermatology-300048765.html
SOURCE RXi Pharmaceuticals Corporation